## **Technical Information**

December 2011

03\_111134e-01/Page 1 of 4 WF-No. 117650

 $^{TM}$  = Trademark of BASF group

# Kollisolv™ PEG Grades

Polyethylene Glycol USP/NF, FCC IV, Macrogols Ph. Eur., Macrogol 400 JP

(former Tradenames Lutrol E 300 and Lutrol E 400)

Liquid polyethylene glycols for the pharmaceutical industry



Pharma Ingredients & Services

### **Chemical nature**

Polyethylene glycols (PEGs) of the general formula

$$HO + CH_2 - CH_2 - O + H$$

Where n = 6 for Kollisolv PEG 300

n = 8 for Kollisolv PEG 400

The number in the name of the product indicates its average molecular weight.

**Trivial names** 

Polyethylene glycol, macrogol, polyglycol, polyoxyethylene and polydiol.

**Description** 

Kollisolv PEG 300 and Kollisolv PEG 400 are colourless, almost odourless and tasteless liquids at room temperature.

The products are manufactured by alkali-catalysed polymerisation of ethylene oxide with subsequent neutralisation of the catalyst.

**Specifications** 

See separate document: "Standard Specification (not for regulatory purposes)" available via BASF's WorldAccount: https://worldaccount.basf.com (registered access).

Regulatory status

Kollisolv PEG 300, Kollisolv PEG 400 meet current Polyethylene Glycol USP/NF, FCC IV and current Macrogols Ph. Eur. monographs.

Kollisolv PEG 400 meets current Macrogol 400 JP monograph.

Solubility

Kollisolv PEG 300, Kollisolv PEG 400 are

- readily soluble in water, ethanol, acetone, glycols and chloroform,

- **insoluble in** ether, paraffin, oils and fats.

Approximate density (20 °C)

Kollisolv PEG 300 approx. 1.13 g/cm<sup>3</sup> Kollisolv PEG 400 approx. 1.13 g/cm<sup>3</sup>

Hygroscopicity

At room temperature and 80% r. h. the following increases in weight were noted over a period of 42 days.

Kollisolv PEG 300 approx. 55% Kollisolv PEG 400 approx. 50%

Fields of application

The low-molecular weight liquid polyethylene glycols Kollisolv PEG 300 and Kollisolv PEG 400 are excellent solvents for a large number of substances that do not readily dissolve in water. They are therefore widely used as solvents and solubilising agents for active substances and excipients in liquid and semi-solid preparations.

It is the ability of PEGs to form complexes with active substances that is responsible for their excellent solvent power. However, equilibrium constants for complex formation vary considerably from one substance to another, and certain drugs such as Penicillin G and Bacitracin can even become inactivated. The effect of the polyethylene glycol on the efficacy and absorbtion of a drug must therefore always be determined in tests. With regard to incompatible substances, please see the remarks in the European Pharmacopoeia, Vol. II/3, Monographs M1, Macrogol 300, p. 3. Polyethylene glycols can also be used to adjust the viscosity of liquid pharmaceutical preparations and ointments, to modify their absorption properties and to stabilise the preparation.

In the manufacture of soft gelatin capsules, liquid macrogols can be used as carriers for dissolved or suspended drugs.

Mixtures of solid and liquid polyethylene glycols can be used as water-soluble bases for ointments, suppositories and ovula.

Because of its good solvent power, Macrogol 400 is used to remove phenol, cresol, aniline and similar compounds from the surface of skin burnt by any of these toxic substances.

For burns from chlorophenols or chlorocresols, a mixture of 2 parts Kollisolv PEG 300 and 1 part ethanol is recommended.

#### Typical formulations

#### 1. Dexpanthenol gel-cream (5%)

#### 1.1. Composition

Dexpantheno	I (BASF)	5 g
Paraffin, liquid	d	10 g
Kollisolv PEG	400	15 g
Kolliphor P 40	)7	18 g
Water		52 g

#### 1.2. Procedure

Dissolve dexpanthenol and Kollisolv PEG 400 in water, add the liquid paraffin and heat to  $60-70\,^{\circ}\text{C}$  with stirring. Slowly stir in Kolliphor P 407 until completely dissolved. Continue gentle stirring while the mixture is cooled to room temperature, to facilitate degassing.

#### 1.3. Properties of the gel

Soft milky gel-cream.

#### 1.4. Physical stability (3 months, 40 °C)

The viscosity and appearance of the gel-creme do not change under these conditions.

## 2. Sulfadoxin solution (2% = 20 mg/ml)

#### 2.1. Composition

I.	Sulfadoxin	2.0 g
	Kollisolv PEG 400	68.0 g
II.	Preservative	q. s.
	Water	30.0 g

#### 2.2. Preparation

Prepare Solution I at 60 °C. Heat Solution II to the same temperature and slowly mix into Solution I. Then cool the mixture.

## 2.3. Properties of the solution

A clear colourless solution of low viscosity is obtained.

#### 2.4. Chemical stability

The solution remained clear after storage for 2 weeks at 6  $^{\circ}$ C and at 20 – 25  $^{\circ}$ C.

Further examples of formulations can be found in the compendium, "Generic Drug Formulations". It is available to order from local BASF offices in looseleaf form and on CD-ROM.

Package sizes

Poylethylene containers of 130 kg and 230 kg, and 1000 kg bulk containers.

PRD-Nos.

Kollisolv PEG 300 30554046 Kollisolv PEG 400 30554047

**Storage** 

Dry, in closed containers

Stability

24 months in closed containers

Note

This document, or any answers or information provided herein by BASF, does not constitute a legally binding obligation of BASF. While the descriptions, designs, data and information contained herein are presented in good faith and believed to be accurate, it is provided for your guidance only. Because many factors may affect processing or application/use, we recommend that you make tests to determine the suitability of a product for your particular purpose prior to use. It does not relieve our customers from the obligation to perform a full inspection of the products upon delivery or any other obligation. NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ARE MADE REGARDING PRODUCTS DESCRIBED OR DESIGNS, DATA OR INFORMATION SET FORTH, OR THAT THE PRODUCTS, DESIGNS, DATA OR INFORMATION MAY BE USED WITHOUT INFRINGING THE INTELLECTUAL PROPERTY RIGHTS OF OTHERS. IN NO CASE SHALL THE DESCRIPTIONS, INFORMATION, DATA OR DESIGNS PROVIDED BE CONSIDERED A PART OF OUR TERMS AND CONDITIONS OF SALE.

December 2011